Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02090179|
Recruitment Status : Completed
First Posted : March 18, 2014
Last Update Posted : June 27, 2016
|Condition or disease|
|MPS IIIB (Sanfilippo B Syndrome)|
|Study Type :||Observational|
|Actual Enrollment :||5 participants|
|Official Title:||Evaluation of Blood Brain Barrier Integrity and Relationship to Structural Brain Abnormalities in MPS IIIB Patients Using Cerebrospinal Fluid/Serum Albumin Index (CSF-AI) and Multimodal Magnetic Resonance Imaging|
|Study Start Date :||December 2013|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||May 2014|
Those with a definitive diagnosis of MPS IIIB (Sanfilippo B Syndrome).
- Blood Brain Barrier integrity in MPS IIIB subjects [ Time Frame: Day 0 ]Blood Brain Barrier integrity in MPS IIIB subjects by estimating the CSF-AI.
- Blood Brain Barrier transfer coefficient [ Time Frame: Day 0 ]The Blood Brain Barrier transfer coefficient will be measured by DCE-MRI in MPS IIIB subjects.
- Structural brain abnormalities in MPS IIIB [ Time Frame: Day 0 ]Structural brain abnormalities in MPS IIIB using imaging and biomarkers related to underlying disease biology of MPS IIIB subjects
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02090179
|Birmingham, United Kingdom|